Molecular Partners AG（MOLN）资讯与事件MOLNMolecular Partners AG

Molecular Partners Presents New Preclinical Data for MP0632

Molecular Partners announced the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer conference. The SITC poster outlines the following key findings: Potent and selective tumor cell killing, with efficacy comparable to a clinical-stage benchmark T-cell engager but a substantially improved safety profile. Safe integration of CD2 co-stimulation, enabling sustained T-cell activity. No detectable impact on primary human mesothelial or epithelial cells and no evidence of mononuclear cell infiltration in the lung pleura of mice expressing human EpCAM and MSLN. These data provide preclinical proof-of-concept that logic-gated Switch-DARPins can selectively target TAAs considered undruggable for TCEs to date, turning MSLN and EpCAM into a "clean" target pair. These results build on previously presented data demonstrating regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tissue expressing only one antigen. In addition, the Switch-DARPin design allowed for safe use of potent co-stimulation for efficient tumor cell killing with low cytokine release profile. Taken together, the preclinical data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, such as ovarian, endometrial, lung and pancreatic cancers. Molecular Partners explores the broad therapeutic potential of its DARPin platforms, including Switch-DARPins inside and outside of oncology, through strategic partnerships and platform-derived spin-out opportunities, representing potential upside beyond its strategic focus on radiotherapeutics.

Molecular Partners Selects MP0730 as Lead Candidate

Molecular Partners announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the tumor-associated antigen CD70. MP0730 is the third program in the company's pipeline of targeted alpha radiotherapeutics, and a first-in-human program is expected to start mid-2027.

Molecular Partners and Orano Med Begin MP0712 Clinical Trial

Molecular Partners and Orano Med announced that the first patients were dosed in the ongoing U.S. multicenter Phase 1/2a study of drug candidate MP0712.